111 related articles for article (PubMed ID: 38401464)
1. REXO2 up-regulation is positively correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.
Zhang T; Zhang R; Zhang Z; Li D; Guo X; Zhang Z; Zhu X; Tan S
Int Immunopharmacol; 2024 Mar; 130():111740. PubMed ID: 38401464
[TBL] [Abstract][Full Text] [Related]
2. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
3. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma.
Wang Z; Chen X; Zhang J; Chen X; Peng J; Huang W
Front Immunol; 2023; 14():1204338. PubMed ID: 37680641
[TBL] [Abstract][Full Text] [Related]
4. EXOSC10 is a novel hepatocellular carcinoma prognostic biomarker: a comprehensive bioinformatics analysis and experiment verification.
Meng ZY; Fan YC; Zhang CS; Zhang LL; Wu T; Nong MY; Wang T; Chen C; Jiang LH
PeerJ; 2023; 11():e15860. PubMed ID: 37701829
[TBL] [Abstract][Full Text] [Related]
5. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.
Xiong C; Wang Z; Wang G; Zhang C; Jin S; Jiang G; Bai D
Invest New Drugs; 2021 Oct; 39(5):1439-1453. PubMed ID: 33942202
[TBL] [Abstract][Full Text] [Related]
6. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
[TBL] [Abstract][Full Text] [Related]
7. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of SLCO4C1 as a biological marker in hepatocellular carcinoma based on anoikis classification features.
Wang T; Guo K; Yang S; Zhang D; Cui H; Yin J; Yuan S; Wang Y; Qi Y; Wu W
Aging (Albany NY); 2024 Jan; 16(2):1440-1462. PubMed ID: 38226966
[TBL] [Abstract][Full Text] [Related]
9. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.
Liu Y; Ma J; Wang X; Liu P; Cai C; Han Y; Zeng S; Feng Z; Shen H
Comput Biol Med; 2023 May; 158():106862. PubMed ID: 37044053
[TBL] [Abstract][Full Text] [Related]
10. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
11. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Li L; Wang X; Ding Y; Hui N; Su B; Yang M
Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
13. Increased long noncoding RNA LINC00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma.
Wang RP; Jiang J; Jiang T; Wang Y; Chen LX
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3291-3301. PubMed ID: 31081082
[TBL] [Abstract][Full Text] [Related]
14. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
15. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of TMEM79 combined with SMG5 is related to prognosis, tumor immune infiltration and drug sensitivity in hepatocellular carcinoma.
Wang Y; Jin Q; Zhang S; Wang Y
Eur J Med Res; 2023 Nov; 28(1):490. PubMed ID: 37936239
[TBL] [Abstract][Full Text] [Related]
17. MiR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma.
Yan TH; Qiu C; Sun J; Li WH
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3038-3046. PubMed ID: 29863248
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma.
Duan X; Li W; Hu P; Jiang B; Yang J; Zhou L; Mao X; Tian B
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33078826
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma.
Wang M; Yang X; Meng Y; Jin Z; Cao J; Xiong L; Xiong Z
Int Immunopharmacol; 2023 Feb; 115():109660. PubMed ID: 36623412
[TBL] [Abstract][Full Text] [Related]
20. Silencing of TRAF5 enhances necroptosis in hepatocellular carcinoma by inhibiting LTBR-mediated NF-κB signaling.
Wu G; Wu F; Zhou YQ; Lu W; Hu FL; Fan X
PeerJ; 2023; 11():e15551. PubMed ID: 37366426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
